Prostate Cancer Biomarker Enrichment and Treatment Selection (NCT03385655)

🧪 Interventions in This Study

• Adavosertib (DRUG)
• Savolitinib (DRUG)
• Darolutamide (DRUG)
• CFI-400945 (DRUG)
• Ipatasertib (DRUG)
• Durvalumab and Tremelimumab (DRUG)
• Carboplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

• Cross Cancer Institute — Edmonton, Alberta
• BCCA - Vancouver Cancer Centre — Vancouver, British Columbia
• QEII Health Sciences Centre — Halifax, Nova Scotia
• Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
• London Regional Cancer Program — London, Ontario
• Ottawa Hospital Research Institute — Ottawa, Ontario
• University Health Network — Toronto, Ontario
• CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
• The Jewish General Hospital — Montreal, Quebec
• Allan Blair Cancer Centre — Regina, Saskatchewan
• Saskatoon Cancer Centre — Saskatoon, Saskatchewan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
• Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
• A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland

Explore by condition: All Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.